What happened
The Food and Drug Administration has approved a second generic version of mifepristone, the drug used in combination with misoprostol to carry out roughly two-thirds of U.S. abortions, drugmaker Evita Solutions announced Thursday. The FDA approved mifepristone in 2000 and the first generic version in 2019.
Who said what
“Approval of a second generic is unlikely to affect access” to mifepristone, The Associated Press said, but the FDA’s quiet approval of Evita’s application “triggered pushback from anti-abortion groups and politicians aligned with the Trump administration.” Students for Life Action called the move “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
This was the “first significant pushback” President Donald Trump has gotten from his “otherwise loyal base of social conservatives,” The Washington Post said. Less than two weeks ago, anti-abortion activists celebrated a promise from FDA Commissioner Marty Makary and Health and Human Services Secretary Robert F. Kennedy Jr. to review mifepristone’s safety. HHS spokesperson Andrew Nixon said Thursday that “the FDA has very limited discretion in deciding whether to approve a generic drug.”
What next?
“I think the intelligent people in the pro-life movement don’t want to go to war with the administration,” a consultant for anti-abortion groups told the Post. “If you do something that embarrasses Trump and the HSS secretary and the high-profile people, then you wind up with Trump digging in his heels — and you don’t want that.” Evita said it expects its version of mifepristone to become available in January.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Did Cop30 fulfil its promise to Indigenous Brazilians?Today’s Big Question Brazilian president approves 10 new protected territories, following ‘unprecedented’ Indigenous presence at conference, both as delegates and protesters
-
The best Christmas theatre shows across the UKThe Week Recommends Tip-top festive ballets, plays and comedies to book up now
-
Crossword: November 20, 2025The daily crossword from The Week
-
More adults are dying before the age of 65Under the radar The phenomenon is more pronounced in Black and low-income populations
-
Scientists have developed a broad-spectrum snake bite antivenomUnder the radar It works on some of the most dangerous species
-
More women are using more testosterone despite limited researchThe explainer There is no FDA-approved testosterone product for women
-
The ‘menopause gold rush’Under the Radar Women vulnerable to misinformation and marketing of ‘unregulated’ products
-
How medical imposters are ruining health studiesUnder the Radar Automated bots and ‘lying’ individuals ‘threaten’ patient safety and integrity of research
-
Doctors sound the alarm about insurance company ‘downcoding’The Explainer ‘It’s blatantly disrespectful,’ one doctor said
-
Can TrumpRx really lower drug prices?Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
‘Nightmare bacteria’ are rapidly spreadingUnder the radar The infections are largely resistant to antibiotics
